Los desarrollos recientes incluyen una aprobación más amplia de lo esperado para Nucala en EPOC y una opinión positiva del CHMP para Blenrep, junto con una nueva adquisición del efimosfermin ...

Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond. Behind the Headlines is a bi-weekly ...

Enter efimosfermin alfa, described as a phase 3-ready, once-monthly injectable fibroblast growth factor 21 (FGF21) analogue with potential across steatotic liver diseases (SLD), including MASH and ...

Recent developments include a broader-than-expected approval for Nucala in COPD and a positive CHMP opinion for Blenrep, alongside a new acquisition of the Phase 3-ready efimosfermin for liver disease ...

Recent developments include a broader-than-expected approval for Nucala in COPD and a positive CHMP opinion for Blenrep, alongside a new acquisition of the Phase 3-ready efimosfermin for liver disease ...

https://lnkd.in/ekKrU6_J GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) ...

Additionally, GSK has acquired efimosfermin alfa, a treatment for steatotic liver disease, from Boston Pharmaceuticals for $1.2 billion upfront. The drug, in phase III trials, is anticipated to launch ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...